ホーム>>Signaling Pathways>> Others>>PA-824

PA-824 (Synonyms: Pretomanid)

カタログ番号GC13561

PA-824(PA-824)は、肺に影響を与える多剤耐性結核の研究に使用される抗生物質です。

Products are for research use only. Not for human use. We do not sell to patients.

PA-824 化学構造

Cas No.: 187235-37-6

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$73.00
在庫あり
5mg
$44.00
在庫あり
25mg
$99.00
在庫あり
100mg
$230.00
在庫あり
500mg
$903.00
在庫あり
1g
$1,743.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PA-824, a bicyclic nitroimidazoles, is an anti-tuberculosis (TB) agent that exerts potent in vitro activity against Mycobacterium tuberculosis with the minimal inhibition concentration (MIC) ranging from 0.015 μg/ml to 0.25 μg/ml and remains actively against a wide range of isolates that are resistant to commonly used anti-TB agents leading to its successful application in the treatment of TB [1].

PA-824 has been found to exhibit bactericidal activity against replicating bacilli and non-replicating bacilli under hypoxic or prolonged culture conditions in a dose dependent fashion through two possible mechanisms, which include PA-824 induced inhibition of ketomycolate synthesis and PA-824 mediated donation of nitric oxide during enzymatic nitro-reduction [1].

References:
[1] Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. doi: 10.1128/AAC.00849-10. Epub 2010 Oct 11.

レビュー

Review for PA-824

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PA-824

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.